Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VE0F
|
|||
| Former ID |
DNC006243
|
|||
| Drug Name |
(S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate
|
|||
| Synonyms |
CHEMBL117658; 1-(PHENYLMETHYL)CYCLOPENTYL[(1S)-1-FORMYLPENTYL]CARBAMATE; 2auz; (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate; BDBM50148292; DB07593; 1-benzylcyclopentyl [(1S)-1-formylpentyl]carbamate; 1-benzylcyclopentyl N-[(2S)-1-oxohexan-2-yl]carbamate; ((S)-1-Formyl-pentyl)-carbamic acid 1-benzyl-cyclopentyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H27NO3
|
|||
| Canonical SMILES |
CCCCC(C=O)NC(=O)OC1(CCCC1)CC2=CC=CC=C2
|
|||
| InChI |
1S/C19H27NO3/c1-2-3-11-17(15-21)20-18(22)23-19(12-7-8-13-19)14-16-9-5-4-6-10-16/h4-6,9-10,15,17H,2-3,7-8,11-14H2,1H3,(H,20,22)/t17-/m0/s1
|
|||
| InChIKey |
ONABDOMWRCXLPX-KRWDZBQOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
| Cathepsin K (CTSK) | Target Info | Inhibitor | [1] | |
| Cathepsin L (CTSL) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | |||
| Antigen processing and presentation | ||||
| Phagosome | ||||
| Proteoglycans in cancer | ||||
| Rheumatoid arthritis | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | Collagen degradation | |||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| Endosomal/Vacuolar pathway | ||||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.